R&D Life sciences real estate: Beyond labs Growth in biotechnology, pharmaceutical R&D, and advanced therapies is driving demand for specialist laboratory space.
R&D Inspection readiness is now a commercial question Manufacturers of advanced therapies are discovering that a digital quality system does more than satisfy inspectors.
Patients Stem the bleeding: Rising to meet the growing demand for CGT... Following World Blood Donor Day, a look at the continued need for more donors of blood, but also cord blood and perinatal tissue, too.
Oncology Sponsored Collaboration & personalisation in rare disease R&D, with AO... For Rare Disease Day, in an AOP Health-sponsored podcast Melissa Fellner, VP of Global Therapeutic Areas, Commercial Operations, discussed their work.
R&D Why Scotland is well-positioned to lead in advanced therapie... The global health burden of complex diseases such as severe lung, liver, and vascular disease is huge, and growing by the second.
Views & Analysis Advanced therapies and the high-profile pricing dilemma The advancements made in drug development over the last decade have seen the arrival of a number of treatments that offer one-time cures and more effective therapies for conditions in small
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.